<!DOCTYPE html>

There is no effective treatment option for the disease, and clinical treatment of GBM is limited by the lack of a scalable, physiologically relevant model for testing therapeutics. ​

To address these problems, we developed...

Novel Organoid-dependent Drug Efficacy Screening

NODES is a high-throughput organoid-based drug screening platform to characterize treatment efficacy in common glioma variants.

Our system is supported by
deep learning pipelines for organoid screening,
oncometabolite mathematical models,
and guidance from patients, clinicians, and other stakeholders

By recapitulating the brain microenvironment, NODES has the potential to accurately characterize drug responses, offering ​new hope to patients in their fight against this lethal disease.